- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07646587
A Study of WIN378 in Participants With Moderate to Severe COPD (Sirius) (Sirius)
10 september 2026 uppdaterad av: Windward Bio
A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of WIN378 in Participants With Moderate - Severe Chronic Obstructive Pulmonary Disease
This study is trying to identify the right dose of a long-acting medicine called WIN378 for people with moderate - severe chronic obstructive pulmonary disease (COPD).
WIN378 blocks the action of a protein called TSLP that causes inflammation in the lung and may contribute to COPD control and symptoms.
The study will test how doses of WIN378 are handled by the body (pharmacokinetics) and assess the safety of the medicine and markers of COPD inflammation in exhaled breath and blood, lung function and COPD control (pharmacodynamics)
Studieöversikt
Status
Rekrytering
Betingelser
Intervention / Behandling
Detaljerad beskrivning
This is a Phase 2a, multicenter, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the safety, tolerability, and pharmacokinetics of WIN378 in adult participants with moderate - severe chronic obstructive pulmonary disease (COPD).
Participants will continue their standard background COPD therapy.
Eligible participants will receive doses of WIN378 or placebo over a 24-week treatment period.
Studietyp
Interventionell
Inskrivning (Beräknad)
105
Fas
- Fas 2
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studiekontakt
- Namn: Juliana Hutchinson, MSc
- Telefonnummer: +4161 551 75 75
- E-post: clinical.trial.enquiry@windwardbio.com
Studieorter
-
-
Buenos Aires
-
Buenos Aires, Buenos Aires, Argentina, C1023AAB
- Rekrytering
- WB Contracted Clinical Research Site
-
Buenos Aires, Buenos Aires, Argentina, C1028AAP
- Rekrytering
- WB Contracted Clinical Research Site
-
Buenos Aires, Buenos Aires, Argentina, C1122AAK
- Rekrytering
- WB Contracted Clinical Research Site
-
Buenos Aires, Buenos Aires, Argentina, C1425BEN
- Rekrytering
- WB Contracted Clinical Research Site
-
Buenos Aires, Buenos Aires, Argentina, C1425FVH
- Rekrytering
- WB Contracted Clinical Research Site
-
Buenos Aires, Buenos Aires, Argentina, C142ABP
- Rekrytering
- WB Contracted Clinical Research Site
-
-
Buenos Aires F.D.
-
Buenos Aires, Buenos Aires F.D., Argentina, C1414AIF
- Rekrytering
- WB Contracted Clinical Research Site
-
Buenos Aires, Buenos Aires F.D., Argentina, C1426ABP
- Rekrytering
- WB Contracted Clinical Research Site
-
-
Mendoza Province
-
Buenos Aires, Mendoza Province, Argentina, M5500AXR
- Rekrytering
- WB Contracted Clinical Research Site
-
Mendoza, Mendoza Province, Argentina, M5500CBA
- Rekrytering
- WB Contracted Clinical Research Site
-
-
Santa Fe Province
-
Rosario, Santa Fe Province, Argentina, S2000KZD
- Rekrytering
- WB Contracted Clinical Research Site
-
Rosario, Santa Fe Province, Argentina, S2013OJN
- Rekrytering
- WB Contracted Clinical Research Site
-
Santa Fe, Santa Fe Province, Argentina, S3000ASF
- Rekrytering
- WB Contracted Clinical Research Site
-
-
-
-
California
-
Los Angeles, California, Förenta staterna, 93534
- Rekrytering
- WB Contracted Clinical Research Site
-
-
Florida
-
Miami Lakes, Florida, Förenta staterna, 33014
- Rekrytering
- WB Contracted Clinical Research Site
-
-
Massachusetts
-
North Dartmouth, Massachusetts, Förenta staterna, 02747
- Rekrytering
- WB Contracted Clinical Research Site
-
-
North Carolina
-
Charlotte, North Carolina, Förenta staterna, 28277
- Rekrytering
- WB Contracted Clinical Research Site
-
-
Oregon
-
Medford, Oregon, Förenta staterna, 97504
- Rekrytering
- WB Contracted Clinical Research Site
-
-
Pennsylvania
-
DuBois, Pennsylvania, Förenta staterna, 15801
- Rekrytering
- WB Contracted Clinical Research Site
-
-
Texas
-
McKinney, Texas, Förenta staterna, 75069
- Rekrytering
- WB Contracted Clinical Research Site
-
Waxahachie, Texas, Förenta staterna, 75165
- Rekrytering
- WB Contracted Clinical Research Site
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Nej
Beskrivning
Inclusion Criteria:
- Adults aged 40 to 80 years
- Post-BD spirometry at screening FEV1/FVC < 0.70 and FEV1 30-80% predicted
- On stable triple inhaled therapy (ICS/LABA/LAMA) for ≥ 3 months
- Former smoker (≥ 10 pack-year history) and abstinence from smoking for ≥ 6 months
- Elevated eosinophil count
- Weight/BMI within allowed range
Exclusion Criteria:
- Clinically significant pulmonary disease other than chronic obstructive pulmonary disease (COPD)
- Clinically significant comorbid medical conditions or infections that, in the investigator's judgment, could affect participant safety or interfere with study conduct
- Clinically significant cardiovascular disease
- Recent respiratory infection or COPD exacerbation
- Exposure to approved or experimental biologic therapies for COPD with less than 5 half-life washout period
- Pregnancy or breastfeeding
- Smoking or diagnosed substance use disorder
- Any condition or circumstance that, in the investigator's opinion, would make participation unsafe or compromise study integrity
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Dubbel
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: WIN378 Dose 1
WIN378 SC injections will be administered
|
WIN378 is a fully human, long-acting monoclonal antibody that targets the ligand of thymic stromal lymphopoietin (TSLP), blocking its activity and thereby reducing airway inflammation and improving COPD control over an extended dosing interval
|
|
Experimentell: WIN378 Dose 2
WIN378 SC injections will be administered
|
WIN378 is a fully human, long-acting monoclonal antibody that targets the ligand of thymic stromal lymphopoietin (TSLP), blocking its activity and thereby reducing airway inflammation and improving COPD control over an extended dosing interval
|
|
Experimentell: Placebo
Placebo SC injections will be administered
|
Placebo matching WIN378
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Number of participants with Adverse Events (AEs)
Tidsram: Week 0 - Week 36
|
Week 0 - Week 36
|
|
|
Number of participants with Serious Adverse Events (SAEs)
Tidsram: Week 0 - Week 36
|
Week 0 - Week 36
|
|
|
Change from baseline in systolic blood pressure (mmHg)
Tidsram: Week 0 - Week 36
|
Week 0 - Week 36
|
|
|
Change from baseline in diastolic blood pressure (mmHg)
Tidsram: Week 0 - Week 36
|
Week 0 - Week 36
|
|
|
Change from baseline in pulse rate (beats/minute)
Tidsram: Week 0 - Week 36
|
Week 0 - Week 36
|
|
|
Change from baseline in respiratory rate (breaths/minute)
Tidsram: Week 0 - Week 36
|
Week 0 - Week 36
|
|
|
Change from baseline in oxygen saturation (%)
Tidsram: Week 0 - Week 36
|
Week 0 - Week 36
|
|
|
Change from baseline in body weight (kg)
Tidsram: Week 0 - Week 36
|
Week 0 - Week 36
|
|
|
Change from baseline in body mass index (kg/m^2)
Tidsram: Week 0 - Week 36
|
Week 0 - Week 36
|
|
|
Change from baseline in body temperature (°C)
Tidsram: Week 0- Week 36
|
Week 0- Week 36
|
|
|
Change from baseline in clinical chemistry laboratory assessments
Tidsram: Week 0 - Week 36
|
Clinical chemistry assessments will include serum chemistry (such as sodium, potassium, urea, creatinine) and liver function parameters, including alanine aminotransferase (ALT), aspartate aminotransferase (AST) and bilirubin.
|
Week 0 - Week 36
|
|
Change from baseline in haematology laboratory parameters
Tidsram: Week 0 - Week 36
|
Haematology assessments will include haemoglobin, white blood cell count, differential white blood cell counts and platelet count
|
Week 0 - Week 36
|
|
Change from baseline in coagulation laboratory parameters
Tidsram: Week 0 - Week 36
|
Coagulation assessments will include activated partial thromboplastin time, international normalised ratio, prothrombin time and fibrinogen
|
Week 0 - Week 36
|
|
Change from baseline in urinalysis parameters
Tidsram: Week 0 - Week 36
|
Urinalysis assessments will include protein, pH, blood, glucose and leucocytes
|
Week 0 - Week 36
|
|
Change from baseline in electrocardiogram QT interval
Tidsram: Week 0 - Week 36
|
Electrocardiogram assessments will include evaluation of QT interval corrected using Fridericia's formula (QTcF)
|
Week 0 - Week 36
|
|
WIN378 Serum concentration (PK)
Tidsram: Week 0 to week 36
|
Week 0 to week 36
|
Sekundära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Change from baseline in Blood Eosinophil Count
Tidsram: Week 0 to Week 24
|
Week 0 to Week 24
|
|
Change in Fractional Exhaled Nitric Oxide (FeNO)
Tidsram: Week 0 to Week 24
|
Week 0 to Week 24
|
|
Change in Pre and Post Bronchodilator Forced Expiratory Volume in 1 Second (FEV1)
Tidsram: Week 0 to Week 24
|
Week 0 to Week 24
|
|
Change in Pre and Post Bronchodilator Forced Vital Capacity (FVC)
Tidsram: Week 0 to Week 24
|
Week 0 to Week 24
|
|
Incidence and magnitude of anti-drug antibodies to WIN 378
Tidsram: Week 0 to Week 36
|
Week 0 to Week 36
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Sponsor
Utredare
- Studierektor: Omar Khwaja, MD, Windward Bio
Publikationer och användbara länkar
Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.
Användbara länkar
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart (Faktisk)
2 juni 2026
Primärt slutförande (Beräknad)
17 december 2027
Avslutad studie (Beräknad)
7 januari 2028
Studieregistreringsdatum
Först inskickad
2 juni 2026
Först inskickad som uppfyllde QC-kriterierna
9 juni 2026
Första postat (Faktisk)
12 juni 2026
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
15 september 2026
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
10 september 2026
Senast verifierad
1 september 2026
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- WB-2102
- U1111-1333-4974 (Annan identifierare: UTN, World Health Organization (WHO))
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
NEJ
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Ja
Studerar en amerikansk FDA-reglerad produktprodukt
Nej
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .